AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
BioVie Advances Lead Drug Candidates with Promising Results
ByAinvest
Saturday, Dec 20, 2025 7:46 am ET1min read
BIVI--
BioVie Inc has advanced its lead drug candidates, Bezisterim and BIV201. Bezisterim, a TNF alpha blocker, is being trialed in Parkinson's disease, long COVID, and Alzheimer's, with promising results including improved muscle control, cognition, and reduced biological aging. A new trial for Parkinson's patients is expected to complete by April or May 2026. BIV201, aimed at ascites related to late-stage liver disease, has shown a 50% reduction in fluid buildup in a phase two trial. BioVie has received FDA feedback and authorizations to move forward into a single phase three trial for BIV201. 2026 is expected to be a catalyst year for the company with multiple readouts and the potential start of a phase three study.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc's editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet